Successful magnesium sulfate tocolysis: Is “weaning” the drug necessary?
- 31 October 1997
- journal article
- clinical trial
- Published by Elsevier BV in American Journal of Obstetrics and Gynecology
- Vol. 177 (4), 742-745
- https://doi.org/10.1016/s0002-9378(97)70261-8
Abstract
OBJECTIVE: Magnesium sulfate is the most commonly used tocolytic agent for preterm labor. A common clinical practice is to slowly discontinue the drug (wean) after successful tocolysis. Our objective was to determine the necessity of this practice. STUDY DESIGN: A prospective, randomized clinical trial was performed from June 1993 to July 1996. After successful magnesium sulfate tocolysis, patients with preterm labor were randomized to two groups: stopping the drug abruptly (no weaning) or gradually weaning the drug (approximately 1 gm every 4 hours). Preterm labor was defined as documented cervical change with regular uterine contractions or regular uterine contractions with a cervix of 2 cm and 75% effacement. The primary outcome variable was the necessity to reinstitute magnesium sulfate therapy within 24 hours of discontinuation of successful tocolysis. RESULTS: One hundred forty-one patients completed the study. No patient in the no-wean group required retocolysis within 24 hours of magnesium discontinuation. However, eight patients in the wean group required retocolysis within 24 hours of magnesium discontinuation ( p = 0.01). Significantly more patients in the wean group had retocolysis during pregnancy (3 vs 12, p = 0.03). Patients in the wean group were also in the labor and delivery unit longer and, as would be anticipated, received magnesium sulfate significantly longer. No differences in the neonatal outcomes were noted between the two groups. Seventy-seven percent of the patients in the study were delivered prematurely. CONCLUSION: This study demonstrated an increased need for retocolysis in the group weaned from magnesium sulfate. We also found that patients in the wean group had an increased labor and delivery time and a longer administration time of magnesium sulfate. Thus weaning magnesium sulfate increases health care cost. The practice of weaning magnesium sulfate does not appear beneficial. (Am J Obstet Gynecol 1997;177:742-5.)Keywords
This publication has 11 references indexed in Scilit:
- Efficacy of oral beta-agonist maintenance therapy in preterm labor: A meta-analysisObstetrics & Gynecology, 1995
- Efficacy and safety of nifedipine versus magnesium sulfate in the management of preterm labor: A randomized studyAmerican Journal of Obstetrics and Gynecology, 1993
- Treatment of Preterm Labor with the Beta-Adrenergic Agonist RitodrineNew England Journal of Medicine, 1992
- Randomized investigation of magnesium sulfate for prevention of preterm birthAmerican Journal of Obstetrics and Gynecology, 1990
- Magnesium tocolysis: Serum levels versus successAmerican Journal of Obstetrics and Gynecology, 1990
- Beta‐mimetics in preterm labour: an overview of the randomized controlled trialsBJOG: An International Journal of Obstetrics and Gynaecology, 1988
- A comparison of ritodrine, terbutaline, and magnesium sulfate for the suppression of preterm laborAmerican Journal of Obstetrics and Gynecology, 1985
- The Parkland Memorial Hospital protocol for treatment of eclampsia: Evaluation of 245 casesAmerican Journal of Obstetrics and Gynecology, 1984
- Magnesium sulfate as a tocolytic agentAmerican Journal of Obstetrics and Gynecology, 1983
- A comparison of magnesium sulfate and alcohol for the prevention of premature laborAmerican Journal of Obstetrics and Gynecology, 1977